domain factors and associated cofactors are important developmental regulators in pattern formation and organogenesis. In addition, overexpression of two LIM-only factors (LMOs) causes acute lymphocytic leukemia. The more recently discovered LMO factor LMO4 is highly expressed in proliferating epithelial cells, and frequently overexpressed in breast carcinoma. Here we show that while LMO4 is expressed throughout mammary gland development, it is dramatically upregulated in mammary epithelial cells during midpregnancy. The LMO coactivator Clim2/Ldb1/NLI showed a similar expression pattern, consistent with the idea that LMO4 and Clim2 act as a complex in mammary epithelial cells. In MCF-7 cells, LMO4 transcripts were upregulated by heregulin, an activator of ErbB receptors that are known to be important in mammary gland development and breast cancer. To test the hypothesis that LMO4 plays roles in mammary gland development, we created an engrailed-LMO4 fusion protein. This fusion protein maintains the ability to interact with Clim2, but acts as a dominant repressor of both basal and activated transcription when recruited to a DNA-regulatory region. When the engrailed-LMO4 fusion protein was expressed under control of the MMTV promoter in transgenic mice, both ductular development in virgin mice and alveolar development in pregnant mice were inhibited. These results suggest that LMO4 plays a role in promoting mammary gland development.
Introduction
The LIM motif, a cysteine-rich zinc-coordinating domain that mediates protein-protein interactions, was originally discovered as a component of homeodomain transcription factors (reviewed in Bach, 2000) . A second class of LIM domain transcription factors, composed almost entirely of two tandem LIM domains, is referred to as LIM-only (LMO) proteins. Two members, LMO1 and LMO2, are oncoproteins found at sites of chromosomal translocations in acute T-cell leukemia (Rabbitts et al., 1999) . LMO proteins do not bind DNA directly, but regulate gene transcription by associating with other transcription factors. This model is supported by studies showing that LMOs, through their LIM domains, exist in a stable complex with helix loop helix (HLH) heterodimeric partner proteins that include TAL1(SCL)/E12 (Valge-Archer et al., 1994; Wadman et al., 1994 Wadman et al., , 1997 Osada et al., 1995 Osada et al., , 1997 Larson et al., 1996; Visvader et al., 1997; Ono et al., 1998; Bao et al., 2000; Herblot et al., 2000; Mead et al., 2001) , and GATA factors (Osada et al., 1995; Wadman et al., 1997; Ono et al., 1998; Mead et al., 2001) . In addition, LIM domains of the LIM homeodomain and LMO proteins interact strongly with cofactors, including the coactivators Clim1 and Clim2/Ldb1/NLI (Agulnick et al., 1996; Jurata et al., 1996; Bach et al., 1997 Bach et al., , 1999 Visvader et al., 1997) , which confer transcriptional activation and promote synergism between DNA-binding proteins (Bach, 2000) .
Based on the prominent expression of Clim2 in proliferating epithelial cells of the epidermis and hair follicles, we discovered LMO4 as a Clim2-interacting protein in the epidermis (Sugihara et al., 1998) . LMO4, simultaneously discovered by other laboratories (Grutz et al., 1998; Kenny et al., 1998) , is the main LIM domain factor expressed in proliferating epithelial cells of the epidermis and hair follicles (Sugihara et al., 1998) . Interestingly, the human LMO4 gene was initially cloned from a breast cancer cDNA library (Racevskis et al., 1999) , and subsequent studies showed it to be overexpressed in more than half of all invasive breast carcinomas (Visvader et al., 2001) . Furthermore, LMO4 and Clim2 overexpression interfered with differentiation of cultured mammary epithelial cells (Visvader et al., 2001) .
The goals of our studies were to establish a dominantnegative LMO4 molecule that can be used to repress transcription of LMO4 target genes and to study the biological function of LMO4 in the mammary gland in vivo. We show that fusion of the repression domain from the Drosophila engrailed homeobox protein (Han and Manley, 1993) to LMO4 creates a strong transcriptional repressor, capable of interfering with basal and activated transcription. Expression of this fusion molecule under the MMTV promoter in mammary glands of transgenic mice leads to inhibition of ductular and alveolar development, suggesting that LMO4 is involved in progression of mammary gland development.
LMO4 is upregulated in mammary epithelial cells during midpregnancy and by heregulin in MCF-7 breast cancer cells
To gain insights into the role of LMO4 in mammary gland biology, we assessed its expression in mouse mammary gland and breast cancer cell lines. In contrast to a previous study employing Northern blot analyses on total RNA (Visvader et al., 2001) , the sensitive RNAse protection assays show that LMO4 transcripts are easily detected in virgin mammary glands and that expression levels remain relatively stable from age 4 weeks to 14 weeks ( Figure 1a) . However, there is dramatic upregulation of LMO4 in mammary glands from midpregnancy, with levels falling late in pregnancy (Figure 1a) , and a moderate increase in LMO4 levels during early lactation (Figure 1a ). Clim2 levels are coordinately regulated during mammary gland development, with the highest levels found in midpregnancy (Figure 1a) , consistent with the idea that LMO4 and Clim2 act as a complex. In situ hybridization studies on mammary gland sections show that LMO4 is primarily expressed in ductular and alveolar epithelial cells (Figure 1b) . Consistent with the RNAse protection assay experiments, LMO4 levels are high at day 14.5 and lower at day 18.5 ( Figure 1b) . The surge in LMO4/ Clim2 transcript levels during midpregnancy suggests an especially important function at this developmental stage, characterized by dramatic epithelial cell proliferation and stromal invasion.
In three different human breast cancer cell lines, LMO4 transcript levels vary from high in the estrogen receptor-negative MDA-MB-231, intermediate in the estrogen receptor-negative MDA-MB-453, to low in the estrogen receptor-positive MCF-7 (Figure 1c ). Estradiol did not increase LMO4 expression in MCF-7 cells (Figure 1c) , consistent with findings in human breast cancer indicating that LMO4 is especially characteristic for estrogen receptor-negative tumors (Gruvberger et al., 2001) . In contrast to the coordinately regulated expression of LMO4 and Clim2 during normal mammary gland development (Figure 1a ), Clim2 levels remain constant in breast cancer cell lines that express high levels of LMO4 transcripts ( Figure 1c ) and protein ( Figure 1d ). These results suggest that relative overexpression of LMO4 compared to Clim2 may be important for LMO4 actions in breast cancer. Since LMO4 may be localized to the cytoplasm under certain conditions (Kenny et al., 1998) , we evaluated its cellular distribution in breast cancer cells by generating MCF-7 cells stably expressing an myc-tagged (MT) LMO4. In these cells, LMO4 is restricted to the nucleus ( Figure 1e ). In contrast to the lack of estrogen regulation, LMO4 expression is stimulated by the ErbB ligand heregulin, which is known to be important for alveolar maturation and proliferation ( Figure 1f ). Heregulin is thought to act through ErbB2-containing heterodimers (Stern, 2003) and its effect was partially blocked by an ErbB2 antibody (Figure 1g ), suggesting a role for ErbB2 in heregulin-mediated upregulation of LMO4.
The observation that LMO4 may be downstream of heregulin/ErbB2 is consistent with findings that the mesenchymally expressed heregulin a, like LMO4, is strikingly upregulated in midpregnancy (Yang et al., 1995) . In addition, heregulin and the ErbB2/ErbB3/ ErbB4 receptors, which have growth-stimulatory roles (Krane and Aguilar et al., 1999) , are particularly important for alveolar morphogenesis (Yang et al., 1995; Jones et al., 1996 Li et al., 2002) . ErbB2 is also overexpressed in 15-40% of breast cancer cases, where it is associated with increased invasiveness and metastasis, as well as poor prognosis (Slamon et al., 1989; Eccles, 2001) . Our findings suggest the possibility that LMO4 may participate in heregulin/ErbB signaling in the mammary gland.
An engrailed-LMO4 fusion protein is capable of protein-protein interactions and acts as a strong transcriptional repressor LMO4 forms a complex with Clim coactivators in epithelial cells and is thought to be recruited to DNAbinding proteins, resulting in transcriptional activation of target genes. We hypothesized that fusing the Drosophila engrailed transcriptional repression domain to LMO4 would create a dominant-negative molecule capable of suppressing LMO4 target genes ( Figure 2a ). When fused to heterologous transcription factors, the engrailed repression domain confers strong transcriptional repression. This quality was successfully used to obtain insights into the biological function of a spectrum of transcriptionally active molecules, including c-Myb (Taylor et al., 1996) , Xenopus tailless (Hollemann et al., 1998) , GATA factors (Sykes et al., 1998; Dasen et al., 1999; Liu et al., 2002) , homeobox factors iroquois3 (Kudoh and Dawid, 2001) and RaxL (Chen and Cepko, 2002) , and b-catenin (Montross et al., 2000) .
To test whether the engrailed-LMO4 fusion protein was capable of protein-protein interactions, we performed co-immunoprecipitation assays in HEK293T cells transfected with expression plasmids encoding tagged LMO4 and Clim2, as well as fusion proteins with LMO4 and Clim2. As expected, Clim2 antiserum precipitated LMO4 in cells transfected with Clim2 and LMO4 (Figure 2b ). In cells cotransfected with tagged VP16-Clim2 and engrailed-LMO4 fusion proteins, both proteins could be precipitated independent of whether the precipitating antibody was directed against VP16-MT- . We conclude that the fusion of the Drosophila engrailed repression domain to LMO4 does not interfere with its ability to interact with Clim proteins. Since natural target genes for LMO4 are unknown, we tested the effectiveness of the engrailed-LMO4 fusion in a GAL reporter system, where we monitored the transcriptional activity of a luciferase reporter gene under the control of GAL DNA-binding sites and a minimal promoter (Sugihara et al., 1998) (Figure 2d ). While LMO4-GAL ( Figure 2d , panel 2) has little effect on the basal activity of the promoter, engrailed-LMO4-GAL ( Figure 2d, panel 3) represses transcription of the reporter gene 29-fold. Furthermore, engrailed-LMO4-GAL could completely overcome a 105-fold activation conferred by the recruitment of a Clim-VP16 fusion protein (Figure 2d , compare panels 5 and 6). Clim alone is a weak activator in this system and the Clim-VP16 fusion protein is used because the viral VP16 transactivation domain can confer strong transactivation to heterologous proteins. In summary, these experiments suggest that an engrailed-LMO4 fusion protein can repress both basal and activated expression of LMO4 target genes, and that this fusion molecule may be useful to test the biological functions of LMO4. S-labeled cRNA probes specific for mouse LMO4 were applied to formalin-fixed tissue, as described (Sugihara et al., 1998) . (c) RNAse protection assays showing expression of LMO4 (top panel), Clim2 (middle panel), and b-actin (lower panel) in the indicated breast cancer cell lines and with estradiol (E2) treatment (20 ng/ml) for the indicated times. MCF-7 cells were grown in the presence of phenol red-free media and charcoal-stripped serum. (d) Western blot of whole-cell extracts from MDA-MB-231 and MCF-7 cells, using rat LMO4 antibody (Sum et al., 2002) and rabbit Clim antisera (Bach et al., 1999) . ( 
Expression of the engrailed-LMO4 fusion protein in mammary gland epithelial cells of mice interferes with mammary gland development
To test the effect of the engrailed-LMO4 molecule on mammary gland development, we placed it under control of the MMTV promoter (Figure 3a) , which has been extensively used to direct a high expression in epithelial cells of mammary glands in transgenic mice (Muller et al., 1988; Guy et al., 1992; Kitsberg and Leder, 1996; Krane and Leder, 1996) . Three independent lines expressed the transgene in mammary gland epithelial cells. Expression of the transgene was found both in virgin and pregnant mammary glands (Figure 3b) , and by immunohistochemistry with an HA antibody expression was predominantly nuclear (Figure 3c) . The relatively constant level of the transgene expression (Figure 3b) is probably because the transgene in this line is upregulated at the very end of pregnancy, as has been described for other MMTV transgenic mice . We examined mammary gland development by whole mount analyses in transgenic mice and compared them to wild-type littermates. Development of transgenic mammary glands of virgin mice was normal at 3-4 weeks (data not shown), but at 6 weeks a mild delay in the progression of ductal development was evident (Figure 3d (Sugihara et al., 2001 ) transfected with expression plasmids encoding HA-tagged engrailed-LMO4 and myc-tagged VP16-Clim2, using IgG (lanes 1 and 3) , MT antibody (lane 2), and HA antibody (lane 4). Western blots were probed with the indicated antibodies. The HA-engrailed-LMO4 fragment was generated in the mammalian expression vector pCMX by fusing the repression domain representing amino acids 2-299 of the Drosophila engrailed gene (Han and Manley, 1993 ) to a HA tag at the Nterminus and the full-length LMO4 coding sequence at the Cterminus. The pCMXGAL-LMO4 and pCMXGAL-engrailed-LMO4 plasmids contain the full-length LMO4 cDNA and the HA-engrailed-LMO4 fusion protein linked to the GAL DNAbinding domain. The pCMXVP16-Clim plasmid contains the Cterminal LIM-interaction domain of Clim1 (Bach et al., 1999) linked to the VP16 transactivation domain. (d) The indicated GAL DNA-binding domain fusion proteins and VP16 fusion proteins were transfected into HEK293T cells with a GAL-luciferase reporter plasmid, using calcium-mediated gene transfer (Sugihara et al., 1998) . The results, expressed as light units, represent the mean and standard deviation from triplicate transfections. IP, immunoprecipitation; W, Western blot Expression of engrailed-LMO4 fusion protein N Wang et al
These data indicate that the engrailed-LMO4 fusion protein causes a transient delay in mammary gland development of virgin mice. In pregnant transgenic mice, a clear delay in alveolar development was evident at day 5.5 ( Figure 4a and b) ; this delay, however, was later overcome, and by day 15.5 lobuloalveolar development was essentially normal (Figure 4b) . No abnormalities were observed during lactation (Figure 4b ) and transgenic females were able to nurse normal size litters. In conclusion, expression of the dominant-negative engrailed-LMO4 fusion protein in the mammary glands of mice results in the slowing of ductal development in virgin mice and a transient inhibition of alveolar development during pregnancy, suggesting that LMO4 plays roles in both ductular and alveolar development in vivo.
The phenotype of the MMTV-HA-engrailed-LMO4 mice may be distinct from the expected phenotype of LMO4 null mice. First, the engrailed-LMO4 fusion protein can suppress the expression of LMO4 target genes both under basal and activated conditions. In contrast, deletion of the LMO4 gene is likely to affect only the genes where LMO4 is actually participating in regulated transcription. Second, while it is generally thought that LMOs in combination with Clims are involved in transactivation, LMO4 may also participate in repression of certain genes, as has been suggested with BRCA1-mediated transcriptional activity (Sum et al., 2002) . The engrailed-LMO4 fusion protein would not be expected to affect these genes since they are already repressed. Finally, LMO4 may also act by binding to and sequestering other proteins in solution, a process the engrailed-LMO4 fusion protein would not be expected to inhibit. Such mechanisms have been proposed for the effect of Drosophila lmo in the fly wing (Zeng et al., 1998) .
The effect of engrailed-LMO4 expression in mammary glands was most clearly observed in early pregnancy, but the defect was overcome towards the end of pregnancy. Such defects, in which mammary gland development is slowed but not blocked, have been previously described in other genetically modified mice such as those with mutations in the ErbB2 gene (Stern, 2003) . However, it is not possible to conclude that the role of LMO4 is restricted to ductular development in virgin mice and alveolar development in early pregnancy, because it is impossible to determine which levels of transgene expression are required to block endogenous LMO4 protein levels. Despite these limitations of the dominant-negative approach, our results strongly The MMTV-HA-engrailed-LMO4 plasmid was created by cloning the HA-engrailed-LMO4 fragment into the EcoR1 site of the MMTV-SV40-BSSK plasmid (Leder et al., 1986) . To generate transgenic mice, the plasmid was cut with Xho1 and Spe1 to remove extraneous sequences, and the purified DNA fragment was then injected into fertilized CB6F1 oocytes, which were implanted into pseudopregnant mice. Of 13 mice born, five contained the MMTV-HA-engrailed-LMO4 sequences, as assessed by PCR with oligonucleotides specific for MMTV sequences. Of these five lines of founder mice, three (lines #1, 2, and 7) expressed the transgene, as assessed by immunohistochemistry with HA antibody on pregnant mammary glands. The three expressing lines were expanded by breeding into CB6F1 mice. Experiments were carried out with transgenic mice derived from lines #1, 2, and 7, which showed a comparable level of abnormality in mammary gland development. (b) RNAse protection assays showing expression of the engrailed-LMO4 transgene from line #7 at the indicated developmental time points. The probe, which corresponded to the Drosophila engrailed part of the fusion molecule, was specific because no signal was observed in mammary glands from wild-type mice (data not shown). (c) HA immunostaining of mammary gland (day 1 of lactation) from MMTV-HA-engrailed-LMO4 mice. Immunostaining of wild-type littermates gave no staining with the HA antibody (data not shown), indicating that the staining is specific. The mammary glands were fixed for 1 h at room temperature in a solution composed of six parts of ethanol, three parts of water, and one part of formaldehyde, followed by storage in 70% ethanol at 41C. Paraffinembedded tissue sections were stained with a monoclonal HA antibody (Covance) using peroxidase. (d) Whole mount staining of the fourth inguinal mammary glands from MMTV-HA-engrailed-LMO4 (TG) mice and littermate wild-type (WT) controls at the indicated developmental stages. Representative results from analyses of 16 (6 weeks) and three (8 weeks) TG mice are shown. The mammary glands were dissected, processed as a whole mount, fixed and stained with hematoxylin as described (Brisken et al., 1999) , and photographed at the same magnification Expression of engrailed-LMO4 fusion protein N Wang et al support roles for LMO4 in both ductular and alveolar development. Moreover, the dominant-negative LMO4 is a promising tool to evaluate the possible role of LMO4 in signaling pathways and in breast cancer.
The etiology of sporadic breast cancers is multifactorial and thought to involve stepwise mutations in several oncogenes and tumor-suppressor genes. The findings described in this paper are of importance because there are parallels between mammary epithelial cells during pregnancy and in breast cancer, and the LMO4 gene is frequently overexpressed in breast cancer. While neoplastic breast epithelial cells clearly have properties distinct from epithelial cells of the developing breast, the two also share similarities such as active proliferation and lack of terminal differentiation (Rudland et al., 1998) . Our studies -showing high expression of LMO4 during a stage in mammary gland development when there is active proliferation and stromal invasion, and the inhibition of these processes with a dominant-negative LMO4 molecule -lend support for the idea that LMO4 upregulation may contribute to the tumorigenic characteristics of mammary epithelial cells (Visvader et al., 2001) .
